ReviewFrontiers in immunology2024
The innate defenders: a review of natural killer cell immunotherapies in cancer.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Spatial and Phenotypic Heterogeneity of ILC Subsets in Mouse Lung Under Type 2 Inflammatory Conditions.European journal of immunology · 2026Article
- The p53 tumor suppressor modulates the expression of proteins that control natural killer cell activity.Cell communication and signaling : CCS · 2026Article
- Circulating immune and biochemical markers predict tumor response to immunotherapy in advanced melanoma and lung cancer.Frontiers in immunology · 2026Article
- Cell-drug conjugates: a novel drug delivery system for cancer therapy.Theranostics · 2026Review
- The impact of neddylation on prognosis in the immune microenvironment of neuroblastoma: a single-cell transcriptomic analysis.Immunologic research · 2025Article
- Review
- UBC4: A Repurposed Drug Regimen for Adjunctive Use During Bladder Cancer Treatment.Biomedicines · 2025Review
- Mechanotransduction of Piezo1 in the cancer microenvironment: implications for NK cell-based immunotherapy.Frontiers in oncology · 2025Review
- Sex-based immunological differences in multisystem inflammatory syndrome in children: potential role of TFrontiers in immunology · 2025Article
- Nucleofection-based screening of chimeric antigen receptor candidates in human natural killer cells.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a condition that has been with us for centuries; however, the therapies that have been developed are often associated with significant toxicity and various side effects. Recent advances in immunology have revealed the potential of the immune system to fight cancer, leading to the emergence of immunotherapy. This review focuses on Natural Killer (NK) cells, innate immune effectors with a remarkable ability to directly kill cancer cells. We will explore the historical context of cancer treatment, the nature of NK cells, and the ways they have been developed to enhance their anti-tumor function, highlighting the limitations of conventional therapies. The therapeutic potential of NK cell-based immunotherapies will also be discussed, emphasizing their unique advantages over other immune cell-based approaches. This review highlights the promising future of NK cell therapies in the fight against cancer and their possible application to assist and improve conventional therapies developed so far.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.